Vanc vs linezolid for MRSA pneumonia

In this large retrospective cohort of VA patients with MRSA pneumonia, 97% of which were treated with vancomycin, outcomes were similar in those treated with vancomycin versus linezolid, including in-hospital survival and readmissions, but LOS was significantly shorter in the linezolid group (abstract). Linezolid is a reasonable option for MRSA pneumonia, and may reduce LOS.

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment